{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:48Z","timestamp":1765887888928},"reference-count":16,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.04.041","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T22:02:27Z","timestamp":1493157747000},"page":"3591-3597","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America"],"prefix":"10.1016","volume":"35","author":[{"given":"Eduardo","family":"Lopez-Medina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Melgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Gaensbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananda S.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavesh R.","family":"Borate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"R\u00fcttimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin J.","family":"Asturias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.041_b0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMp1514467","article-title":"World free of polio \u2013 the final steps","volume":"374","author":"Patel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.041_b0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.041_b0015","unstructured":"Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. Geneva, Switzerland: World Health Organization; 2013. <http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf> [accessed 23.01.17]."},{"key":"10.1016\/j.vaccine.2017.04.041_b0020","first-page":"145","article-title":"Polio vaccines: WHO position paper \u2013 March, 2016","volume":"91","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.04.041_b0025","unstructured":"World Health Organization. SAGE discussion and statement in relation with the IPV supply situation. <http:\/\/www.who.int\/immunization\/sage\/meetings\/2016\/april\/presentations_background_docs\/en\/> [accessed 23.01.17]."},{"key":"10.1016\/j.vaccine.2017.04.041_b0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.041_b0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O\u2019Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.041_b0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11606-010-1513-8","article-title":"Understanding equivalence and noninferiority testing","volume":"26","author":"Walker","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2017.04.041_b0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2017.04.041_b0050","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","article-title":"Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses","volume":"162","author":"Faden","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.041_b0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.aje.a115009","article-title":"Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines","volume":"128","author":"McBean","year":"1988","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.04.041_b0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00006454-199707000-00010","article-title":"Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b\/hepatitis B vaccine","volume":"16","author":"Halsey","year":"1997","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl. 1","key":"10.1016\/j.vaccine.2017.04.041_b0065","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/infdis\/175.Supplement_1.S228","article-title":"Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group","volume":"175","author":"Modlin","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.041_b0070","doi-asserted-by":"crossref","first-page":"161A","DOI":"10.1203\/00006450-199804001-00954","article-title":"A randomized study of the safety and immunogenicity of DTPa-HB-IPV vaccine administered as three doses or in a sequential IPV\/OPV schedule at 2, 4, and 6 months of age [Abstract]","volume":"43","author":"Yeh","year":"1998","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2017.04.041_b0075","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00006454-200111001-00004","article-title":"Interchangeability of vaccines","volume":"20","author":"Feldman","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.041_b0080","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T06:28:04Z","timestamp":1535869684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":16,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17305194"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}